Conference Call with Ipca Laboratories Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q2FY26 results Consolidated Net total Income up 9% at Rs 2,584.36 crore. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.68% in Q2FY26 as against @ 19.10% in Q2FY25. Consolidated Net Profit at Rs 282.57 crore (after exceptional items) up 23%. Exports Income up 7% at Rs 813.65 crore. Indian formulations income up 8% at Rs 1018.90 crore. Result PDF
Conference Call with Ipca Laboratories Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q1FY26 results Revenue from Operations: Rs 2,308.85 crore compared to Rs 2,092.63 crore during Q1FY25, a change of 10%. EBITDA: Rs 424.58 crore compared to Rs 387.49 crore during Q1FY25, change 10%. PBT: Rs 234.42 crore compared to Rs 198.98 crore during Q1FY25, change 18%. PAT: Rs 233.21 crore compared to Rs 192.24 crore during Q1FY25, change 21%. EPS: Rs 9.19 for Q1FY26. Result PDF